Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug247 | Aerosol-reducing Mask Wiki | 0.38 |
| drug116 | ALLOCETRA-OTS Wiki | 0.38 |
| drug4079 | Standard Mask Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2286 | LEAF-4L6715 Wiki | 0.38 |
| drug5055 | microcirculation recording Wiki | 0.38 |
| drug2466 | MMR vaccine Wiki | 0.38 |
| drug686 | Breastfeeding self-efficacy (BSE) Wiki | 0.38 |
| drug3155 | Phage Therapy Wiki | 0.38 |
| drug866 | CT-Scan Wiki | 0.27 |
| drug4857 | blood donation SMS Wiki | 0.22 |
| drug453 | Azithromycin Wiki | 0.06 |
| drug3195 | Placebo Wiki | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018805 | Sepsis NIH | 0.72 |
| D011552 | Pseudomonas Infections NIH | 0.38 |
| D004461 | Eclampsia NIH | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011645 | Puerperal Infection NIH | 0.38 |
| D063130 | Maternal Death NIH | 0.38 |
| D000071074 | Neonatal Sepsis NIH | 0.38 |
| D066087 | Perinatal Death NIH | 0.38 |
| D011225 | Pre-Eclampsia NIH | 0.27 |
| D046110 | Hypertension, Pregnancy-Induced NIH | 0.27 |
| D011251 | Pregnancy Complications, Infectious NIH | 0.22 |
| D016470 | Bacteremia NIH | 0.22 |
| D018746 | Systemic Inflammatory Response Syndrome NIH | 0.19 |
| D003643 | Death, NIH | 0.19 |
| D011248 | Pregnancy Complications NIH | 0.12 |
| D006973 | Hypertension NIH | 0.08 |
| D011014 | Pneumonia NIH | 0.06 |
| D011024 | Pneumonia, Viral NIH | 0.04 |
| D007239 | Infection NIH | 0.03 |
| D013577 | Syndrome NIH | 0.03 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.03 |
| D055371 | Acute Lung Injury NIH | 0.03 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.03 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100806 | Sepsis HPO | 0.72 |
| HP:0003811 | Neonatal death HPO | 0.38 |
| HP:0100601 | Eclampsia HPO | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0040187 | Neonatal sepsis HPO | 0.38 |
| HP:0100603 | Toxemia of pregnancy HPO | 0.27 |
| HP:0000822 | Hypertension HPO | 0.08 |
| HP:0002090 | Pneumonia HPO | 0.06 |
Navigate: Correlations HPO
There are 7 clinical trials
Maternal and neonatal infections are among the most frequent causes of maternal and neonatal deaths, and current antibiotic strategies have not been effective in preventing many of these deaths. Recently, a randomized clinical trial conducted in a single site in The Gambia showed that treatment with oral dose of 2 g azithromycin vs. placebo for all women in labor reduced selected maternal and neonatal infections. However, it is unknown if this therapy reduces maternal and neonatal sepsis and mortality. The A-PLUS trial includes two primary hypotheses, a maternal hypothesis and a neonatal hypothesis. First, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce maternal death or sepsis. Second, a single, prophylactic intrapartum oral dose of 2 g azithromycin given to women in labor will reduce intrapartum/neonatal death or sepsis.
Description: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.
Measure: Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group. Time: within 6 weeks (42 days)Description: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group
Measure: Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group Time: 4 weeks (28 days) post-deliveryDescription: Fever (>100.4°F/38°C) in addition to one or more of the following: fetal tachycardia ≥160 bpm, maternal tachycardia >100 bpm, tender uterus between contractions, or purulent/foul smelling discharge from uterus prior to delivery.
Measure: Incidence of chorioamnionitis Time: prior to deliveryDescription: Fever (>100.4°F/38°C) in addition to one or more of maternal tachycardia >100 bpm, tender uterine fundus, or purulent/foul smelling discharge from uterus after delivery.
Measure: Incidence of endometritis Time: within 42 days post-deliveryDescription: Wound infection (Purulent infection of a perineal or Cesarean wound with or without fever. In the absence of purulence, requires presence of fever >100.4°F/38°C and at least one of the following signs of local infection: pain or tenderness, swelling, heat, or redness around the incision/laceration); Abdominopelvic abscess (Evidence of pus in the abdomen or pelvis noted during open surgery, interventional aspiration or imaging); Pneumonia (Fever >100.4°F/38°C and clinical symptoms suggestive of lung infection including cough and/or tachypnea >24 breaths/min or radiological confirmation); Pyelonephritis (Fever >100.4°F/38°C and one or more of the following: urinalysis/dip suggestive of infection, costovertebral angle tenderness, or confirmatory urine culture); Mastitis/breast abscess or infection (Fever >100.4°F/38°C and one or more of the following: breast pain, swelling, warmth, redness, or purulent drainage).
Measure: Incidence of other infections Time: within 42 days post-deliveryDescription: Use of subsequent maternal antibiotic therapy after randomization to 42 days postpartum for any reason.
Measure: Incidence of use of subsequent maternal antibiotic therapy Time: after randomization to 42 days post-deliveryDescription: Time from drug administration until initial discharge after delivery (time may vary by site).
Measure: Maternal initial hospital length of stay Time: within 42 days post-deliveryDescription: Maternal readmissions within 42 days of delivery
Measure: Incidence of maternal readmissions Time: within 42 days post-deliveryDescription: Maternal admission to special care units
Measure: Incidence of maternal admission to special care units Time: within 42 days post-deliveryDescription: Maternal unscheduled visit for care
Measure: Incidence of maternal unscheduled visit for care Time: within 42 days post-deliveryDescription: Maternal GI symptoms including nausea, vomiting, and diarrhea and other reported side effects.
Measure: Incidence of maternal GI symptoms Time: within 42 days post-deliveryDescription: Maternal death due to sepsis using the Global Network algorithm for cause of death
Measure: Incidence of maternal death due to sepsis Time: within 42 days post-deliveryDescription: Incidence of other neonatal infections.
Measure: Incidence of other neonatal infections (e.g. eye infection, skin infection) Time: within 42 days post-deliveryDescription: Neonatal initial hospital length of stay, defined as time of delivery until initial discharge (time may vary by site).
Measure: Neonatal initial hospital length of stay Time: within 28 days of deliveryDescription: Neonatal readmissions within 42 days of delivery
Measure: Incidence of neonatal readmissions Time: within 42 days of deliveryDescription: Neonatal admission to special care units
Measure: Incidence of neonatal admission to special care units Time: within 28 days of deliveryDescription: Neonatal unscheduled visit for care
Measure: Incidence of neonatal unscheduled visit for care Time: within 42 days post-deliveryDescription: Neonatal death due to sepsis using the Global Network algorithm for causes of death
Measure: Incidence of neonatal death due to sepsis Time: within 28 days of deliveryDescription: Pyloric stenosis within 42 days of delivery, defined as clinical suspicion based on severe vomiting leading to death, surgical intervention (pyloromyotomy) as verified from medical records, or radiological confirmation.
Measure: Incidence of pyloric stenosis within 42 days of delivery Time: within 42 days of deliveryThis is an open label phase II study of treatment with LEAF-4L6715 in patients who experience severe acute respiratory distress syndrome (ARDS) and are receiving artificial respiratory support due to COVID-19, Sepsis or other Causes. The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in patients treated with LEAF-4L6715.
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of myeloid-derived suppressor cells (MDSCs) Time: 14 days post-vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 30 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 60 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 12 months post vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 14 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 30 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 60 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 12 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 14 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 30 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 60 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 3 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 4 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 5 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 6 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 7 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 8 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 9 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 10 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 11 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 12 months post-vaccinationHypertensive disorders of pregnancy (HDP) are increasingly recognized sex-specific risk factors for premature cardiovascular disease (CVD) in women. HDP, including preeclampsia and gestational hypertension, confer a 2- to 3-fold increase in the risk of chronic hypertension and ischemic heart disease 10-15 years after delivery. Observational data suggest that breastfeeding can lower maternal blood pressure (BP), risk of metabolic syndrome, and other markers of cardiovascular risk in the short term and long term, possibly by helping to re-set the metabolic changes of pregnancy. We recently demonstrated an 11% reduction in the risk of metabolic syndrome among postpartum women with a variety of complications in pregnancy, including HDP, who breastfed for > 6 months, compared to those who did not breastfeed and those who breastfed for shorter durations. An analysis of 622 postpartum women at Kingston General Hospital showed that breastfeeding women had nearly a 6-mmHg lower systolic BP than women who did not breastfeed with an apparent dose-response effect of breastfeeding duration. Women with pregnancy complications including HDP are vulnerable to early weaning. Interactive, multi-modal approaches targeting a mother's breastfeeding self-efficacy (i.e., confidence about breastfeeding) have been effective in healthy postpartum women. However, breastfeeding support interventions have not yet been tested specifically in HDP women, who stand to derive substantial benefit from breastfeeding. This is an important area to study since nurse-led breastfeeding supportive interventions can be widely applied to the postpartum care of women with HDP and can be integrated into comprehensive CVD risk reduction programs for these women. Our primary outcome is postpartum BP, since hypertension is a key mediating factor in women's heart health. We conducted a feasibility study of a breastfeeding self-efficacy intervention to enhance breastfeeding outcomes among women with HDP showing feasibility (achieving pre-defined targets of a recruitment rate of >50% , attrition rates of < 30%), and > 70% participant satisfaction with the intervention, measured at the 6-month time point. Additionally, data showed trends in both systolic and diastolic BP favoring the intervention group. We are now conducting a multi-site open-label randomized trial to assess for a difference in blood pressure and breastfeeding between groups, and to serve as a cohort of HDP women for longitudinal follow-up.
Description: Evaluate whether a nurse-led BSE intervention will result in a lower systolic and/or diastolic BP 12 months postpartum
Measure: Systolic and/or diastolic BP, in mmHg. Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in a lower need for antihypertensive therapy
Measure: Use of antihypertensive therapy Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in longer duration of exclusive breastfeeding
Measure: Duration of exclusive breastfeeding (weeks) Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in higher rates of any continued breastfeeding at 6 months
Measure: The proportion who breastfeed (exclusive or non-exclusive) Time: 12 monthsDescription: Evaluate whether a nurse-led BSE intervention will result in lower metabolic syndrome
Measure: Metabolic syndrome Time: 12 monthsA phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled, dose- finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.
Description: Number and severity of AEs and SAEs throughout 28 days follow up period
Measure: To compare the safety of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Change from baseline in SOFA score throughout 28 days
Measure: To compare the efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients Time: 28 daysDescription: Vasopressor-free days over 28 days.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Ventilator-free days over 28 days
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients. Time: 28 daysDescription: Days without renal replacement therapy (dialysis).
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Time in ICU and time in hospital
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number of days with creatinine ≤ Baseline levels +20%.
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: All-cause mortality at Day 28 following first dose
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Changes in CRP levels
Measure: compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients Time: 28 daysDescription: Number and severity of AEs and Serious Adverse Events (SAEs) throughout 12 months follow up period
Measure: Assess long term safety follow up Time: 12 monthsBacteriophage treatment in Covid-19 patients being treated with Anti-Microbials for Pneumonia or Bacteremia/Septicemia.
This prospective observational pilot study investigates circulatory coherence in patients with COVID and non-COVID sepsis by comparison of microcirculation, endothelial glycocalyx, and clinical course
Description: PPV describes microcirculation dysfunction
Measure: change in Proportion of Perfused Vessels (PPV) parameter Time: 1st, 2nd and 3rd dayDescription: Syndecan-1 is a marker of endothelial glycocalyx
Measure: change in Syndecan-1 serum concentration Time: 1st, 2nd and 3rd dayDescription: albuminuria is a marker of glomerular endothelial cells dysfunction
Measure: change in albuminuria Time: 1st, 2nd and 3rd dayDescription: mortality in 28 days from ICU admission
Measure: mortality in 28 days Time: 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports